Tocagen Inc (NASDAQ:TOCA) Has Decline in Shorts

October 13, 2018 - By Peter Erickson

The stock of Tocagen Inc (NASDAQ:TOCA) registered a decrease of 3.45% in short interest. TOCA’s total short interest was 1.03 million shares in October as published by FINRA. Its down 3.45% from 1.06 million shares, reported previously. With 183,100 shares average volume, it will take short sellers 6 days to cover their TOCA’s short positions. The short interest to Tocagen Inc’s float is 5.82%.

The stock increased 0.87% or $0.11 during the last trading session, reaching $12.81. About 248,664 shares traded or 1.13% up from the average. Tocagen Inc. (NASDAQ:TOCA) has risen 1.41% since October 13, 2017 and is uptrending. It has underperformed by 14.21% the S&P500.

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. The company has market cap of $255.58 million. The Company’s cancer-selective gene therapy platform is built on retroviral replicating vectors , which are designed to deliver therapeutic genes into the DNA of cancer cells. It currently has negative earnings. The company??s lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG).

More news for Tocagen Inc. (NASDAQ:TOCA) were recently published by: Benzinga.com, which released: “46 Biggest Movers From Yesterday” on October 10, 2018. Seekingalpha.com‘s article titled: “Tocagen completes enrollment in Toca 5 Phase 3 brain cancer trial” and published on September 19, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>